Key Highlights

● Ascendis Pharma reports third-quarter results before Thursday's opening bell.

● A management conference call is set for 8 a.m. ET.

● 456 companies report on Nov. 12, including 157 before the open.

● Results had not been seen as of the pre-market research cutoff.

Ascendis Pharma (NASDAQ:ASND) is scheduled to put its third-quarter numbers in front of investors before Thursday's opening bell, with a management conference call set for 8 a.m. ET. As of the research cutoff at about 7:30 a.m. ET, the results had not been seen, so the figures and the share reaction remain pending.

The timing puts the Danish drugmaker's report squarely inside one of the busiest Earnings mornings of the season. Earnings calendars count 456 companies reporting on Nov. 12, including 157 before the open, and the broader tape is being shaped by turmoil around Nvidia (NASDAQ:NVDA) rather than by healthcare news.

What Ascendis does and why the quarter matters

Ascendis, whose American depositary shares trade on the Nasdaq and count toward the Nasdaq Composite, builds drugs on its TransCon technology, a platform designed to extend how long a therapy works in the body. Its commercial portfolio includes YORVIPATH for hypoparathyroidism, SKYTROFA for growth hormone deficiency and the more recently launched YUVIWEL.

The company enters the print with strong momentum. In its second-quarter report in August, Ascendis posted total Revenue of about €339 million and product revenue of roughly €315 million, up 105% from a year earlier. YORVIPATH alone contributed about €252 million, and the company reported a non-IFRS operating profit of about €92 million after a loss in the prior-year period.

That shift from heavy losses toward operating profit is the core of the Investment debate. A year ago, in its third quarter of 2025, Ascendis reported revenue of about €214 million and a loss per share of €1.00, which shows how quickly the revenue base has grown since the YORVIPATH launch.

What investors will look for

Key questions for the report include whether YORVIPATH Demand kept compounding in the third quarter, how the early YUVIWEL launch is tracking and whether the company can keep operating profit positive as launch spending rises. In the second quarter, SG&A expense climbed to about €173 million from €108 million, reflecting commercial investment.

Pipeline updates may also matter. Ascendis said in August that all 21 children in its COACH trial, which combines TransCon CNP with TransCon hGH, completed 78 weeks of treatment, and that it expected a Phase 3 trial in pediatric achondroplasia to begin in the fourth quarter of 2026.

The Balance Sheet is another thread. Ascendis reported €812 million in cash at the end of June and said its $575 million of 2028 convertible notes had been redeemed or converted, according to the same summary.

What to Watch Next for Ascendis Pharma

The setup for Growth Stocks is not friendly this morning. Nasdaq-100 futures were down 0.63% and S&P 500 futures down 0.31% at about 5:26 a.m. ET, as Nvidia slid on reports that its board was weighing the future of CEO Jensen Huang. Healthcare is not at the center of that selloff, but risk appetite across the Nasdaq could color how any biotech surprise is received.

Rates are another headwind for long-duration healthcare names. The 10-year Treasury Yield was near 5% Thursday morning, and CME FedWatch data showed markets pricing roughly 90% odds of a quarter-point Fed hike in December.

Risks specific to Ascendis include launch execution, reimbursement in new markets, currency swings for a euro-reporting company with a US listing, and regulatory timelines for pipeline candidates. The next markers are the 8 a.m. ET call, the first trades at 9:30 a.m. ET and Friday's producer price data, which could move rate-sensitive sectors again.